IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage kidney disease in adolescents and young adults. The 2025 KDIGO clinical practice guideline updates represent a major paradigm shift, lowering the optimal proteinuria target from <1.0 g/day to <0.3 g/day and emphasizing earlier escalation at persistent proteinuria ≥0.5 g/day, even in the absence of rapid eGFR decline. Notably, these guidelines recommend a simultaneous, dual-pathway approach, combining optimized supportive therapy (RAAS inhibition, SGLT2 inhibitors) with the timely introduction of immunomodulatory or disease-modifying agents in high-risk patients. However, real-world practice across Asia has not yet caught up. Explore this series for practical strategies to support patient selection and the integration of emerging agents into individualized care.

IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage kidney disease in adolescents and young adults. The 2025 KDIGO clinical practice guideline updates represent a major paradigm shift, lowering the optimal proteinuria target from <1.0 g/day to <0.3 g/day and emphasizing earlier escalation at persistent proteinuria ≥0.5 g/day, even in the absence of rapid eGFR decline. Notably, these guidelines recommend a simultaneous, dual-pathway approach, combining optimized supportive therapy (RAAS inhibition, SGLT2 inhibitors) with the timely introduction of immunomodulatory or disease-modifying agents in high-risk patients. However, real-world practice across Asia has not yet caught up. Explore this series for practical strategies to support patient selection and the integration of emerging agents into individualized care.

IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage kidney disease in adolescents and young adults. The 2025 KDIGO clinical practice guideline updates represent a major paradigm shift, lowering the optimal proteinuria target from <1.0 g/day to <0.3 g/day and emphasizing earlier escalation at persistent proteinuria ≥0.5 g/day, even in the absence of rapid eGFR decline. Notably, these guidelines recommend a simultaneous, dual-pathway approach, combining optimized supportive therapy (RAAS inhibition, SGLT2 inhibitors) with the timely introduction of immunomodulatory or disease-modifying agents in high-risk patients. However, real-world practice across Asia has not yet caught up. Explore this series for practical strategies to support patient selection and the integration of emerging agents into individualized care.

IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage kidney disease in adolescents and young adults. The 2025 KDIGO clinical practice guideline updates represent a major paradigm shift, lowering the optimal proteinuria target from <1.0 g/day to <0.3 g/day and emphasizing earlier escalation at persistent proteinuria ≥0.5 g/day, even in the absence of rapid eGFR decline. Notably, these guidelines recommend a simultaneous, dual-pathway approach, combining optimized supportive therapy (RAAS inhibition, SGLT2 inhibitors) with the timely introduction of immunomodulatory or disease-modifying agents in high-risk patients. However, real-world practice across Asia has not yet caught up. Explore this series for practical strategies to support patient selection and the integration of emerging agents into individualized care.

2025 delivered an expanded approval for Cushing syndrome for one agent, a complete response letter for another, and deeper insights on the prevalence of Cushing syndrome (or hypercortisolism) in people with difficult-to-control metabolic conditions. 2026 promises to be jam packed with further insights on Cushing syndrome prevalence and data for emerging drugs. Join our faculty as they review advances from 2025 and look ahead to what’s coming in 2026.

This activity examines the evolving role of tyrosine kinase inhibitors (TKIs) in treating exudative retinal diseases such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Experts discuss limitations of current anti-VEGF therapies, emphasizing challenges with durability and adherence. The series further explores TKI mechanisms and their formulation into sustained-release delivery systems. Detailed overviews of clinical programs (eg, LUGANO, LUCIA, SOL-1, SOL-R) highlight ongoing phase 3 studies evaluating efficacy and treatment intervals. Real-world case discussions further illustrate patient types who may benefit from these investigational agents. The conversation concludes with considerations for integrating TKIs into future practice.

*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 0.75.

This activity examines the evolving role of tyrosine kinase inhibitors (TKIs) in treating exudative retinal diseases such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Experts discuss limitations of current anti-VEGF therapies, emphasizing challenges with durability and adherence. The series further explores TKI mechanisms and their formulation into sustained-release delivery systems. Detailed overviews of clinical programs (eg, LUGANO, LUCIA, SOL-1, SOL-R) highlight ongoing phase 3 studies evaluating efficacy and treatment intervals. Real-world case discussions further illustrate patient types who may benefit from these investigational agents. The conversation concludes with considerations for integrating TKIs into future practice.

*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 0.75.

This activity examines the evolving role of tyrosine kinase inhibitors (TKIs) in treating exudative retinal diseases such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Experts discuss limitations of current anti-VEGF therapies, emphasizing challenges with durability and adherence. The series further explores TKI mechanisms and their formulation into sustained-release delivery systems. Detailed overviews of clinical programs (eg, LUGANO, LUCIA, SOL-1, SOL-R) highlight ongoing phase 3 studies evaluating efficacy and treatment intervals. Real-world case discussions further illustrate patient types who may benefit from these investigational agents. The conversation concludes with considerations for integrating TKIs into future practice.

*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 0.75.

This activity examines the evolving role of tyrosine kinase inhibitors (TKIs) in treating exudative retinal diseases such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Experts discuss limitations of current anti-VEGF therapies, emphasizing challenges with durability and adherence. The series further explores TKI mechanisms and their formulation into sustained-release delivery systems. Detailed overviews of clinical programs (eg, LUGANO, LUCIA, SOL-1, SOL-R) highlight ongoing phase 3 studies evaluating efficacy and treatment intervals. Real-world case discussions further illustrate patient types who may benefit from these investigational agents. The conversation concludes with considerations for integrating TKIs into future practice.

*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 0.75.

This activity examines the evolving role of tyrosine kinase inhibitors (TKIs) in treating exudative retinal diseases such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Experts discuss limitations of current anti-VEGF therapies, emphasizing challenges with durability and adherence. The series further explores TKI mechanisms and their formulation into sustained-release delivery systems. Detailed overviews of clinical programs (eg, LUGANO, LUCIA, SOL-1, SOL-R) highlight ongoing phase 3 studies evaluating efficacy and treatment intervals. Real-world case discussions further illustrate patient types who may benefit from these investigational agents. The conversation concludes with considerations for integrating TKIs into future practice.

*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 0.75.